Case Report

Massive bleeding of a jejunal gastrointestinal stromal tumour: a rare case of a life-threatening presentation

Schauki Mahmoud¹,* and Hosam Salman²

¹Department of General Surgery, Albassel Hospital, Tartous, Syrian Arab Republic and ²Department of Histopathology, Albassel Hospital, Tartous, Syrian Arab Republic

*Correspondence address. General Surgery Department, Albassel hospital, Tartous, Syrian Arab Republic. Tel: 00963 938154550; Fax: 00963 432555048; E-mail: mahmoudschauki@gmail.com

Abstract

A jejunal gastrointestinal stromal tumour (GIST) is a rare neoplasm of the gastrointestinal tract. Massive bleeding due to a jejunal GIST is a diagnostic challenge and could present as a life-threatening situation needing urgent intervention. A 54-year-old woman presented with episodes of melaena and haematochezia for the previous 3 days. An oesophago-duodenoscopy was inconclusive. A contrast computed tomography (CT) scan showed a well-defined extraluminal mass in the proximal jejunum suggestive of a bleeding GIST. Her haemodynamic state deteriorated despite initial supportive therapy including a blood transfusion. An urgent laparotomy to excise the jejunal mass was performed. Histopathology and immunohistochemical studies confirmed the diagnosis. She subsequently received adjuvant imatinib therapy. She has remained symptom free at 5 months post-op. We therefore present a rare case of obscure massive gastrointestinal bleeding due to a jejunal GIST. The CT scan was the most effective investigation to detect the source of bleeding in this case.

INTRODUCTION

Gastrointestinal stromal tumours (GISTs) are rare neoplasms arising from the interstitial cells of Cajal in the gastrointestinal (GI) tract. GISTs account for only 0.1—3% of all neoplasms in the GI tract [1]. The majority of GISTs are located in the stomach (60—70%), whereas 20—30% are found in the small intestine and rarely in the oesophagus, colon, rectum and retroperitoneum [2].

Intermittent GI bleeding is the most common manifestation of a gastrointestinal stromal tumour (GIST) (42%), but massive life-threatening bleeding needing urgent intervention is a rare presentation [3]. Abdominal pain (20%) and obstruction (10%) are other potential manifestations. In all, ~20% of GISTs are asymptomatic and are discovered incidentally during abdominal imaging or intraoperatively [2].

Immunohistochemical staining for CD 117 antigen is positive in ~95% of GISTs and is considered the mainstay of diagnosis [3].

CASE REPORT

A 54-year-old woman presented with a history of multiple episodes of melaena and haematochezia accompanied by colicky abdominal pain and fatigue for the previous 3 days. Other than hypertension she did not have any other comorbidity. On primary physical examination she was pale and had a slight tachycardia but was normotensive. Abdominal examination was unremarkable. Digital rectal examination confirmed melaena stool mixed with fresh blood. Laboratory tests revealed a low haemoglobin of 7.2 g/dl. Clotting tests were normal. The patient was commenced on IV fluids and a transfusion with packed red blood cells. Emergency gastroscopy to the third part of the duodenum did not show any evidence of active bleeding. She continued to pass large amounts of melaena and fresh blood and her haemoglobin was noted to have dropped to 5.4 g/dl. A colonoscopy was decided against. She received further packed...
red blood cells and underwent an urgent computed tomography (CT) scan with oral and IV contrast. This showed a well-defined homogenous extraluminal mass (4 × 3.5 cm) in the proximal jejunum with mesenteric neovascularisation. There was no evidence of intra-abdominal metastases or enlarged lymph nodes (Figs 1 and 2). These findings were most suggestive of a bleeding GIST. Angiography and embolisation facilities were not available in our institution. The patient was becoming unstable and so an urgent laparotomy was required.

At laparotomy we found a hypervascular 4 × 3.5 cm mass in the proximal jejunum ~15 cm from the ligament of Treitz. The mass was protruding from the anti-mesenteric border and was of a very firm consistency. The small and large bowel was seen to be loaded with blood (Fig. 3). As per the CT scan there was no sign of any intraperitoneal metastases or enlarged lymph nodes. The mass was resected with a margin of 4 cm on either side and a primary anastomosis performed. The postoperative course was uneventful and she was discharged on Day 7 post op.

Histology showed a mixed cell type jejunal GIST with a mitotic index of <5/50 HPF—High Power Fields, clear resection margins and an intact tumour capsule (Figs 4 and 5).

Immunohistochemical staining for CD 117 was positive confirming the diagnosis of a GIST (Fig. 6). Molecular assessment for c-KIT D816V and PDGFRA D842V mutations (markers of resistance to adjuvant imatinib therapy) were performed and were negative. Thus adjuvant imatinib 400 mg/day was commenced.

The patient remains symptom free at 5 months follow-up and will undergo surveillance abdominal CT scans at intervals of 6 months.
Massive bleeding of a jejunal gastrointestinal stromal tumour

**DISCUSSION**

Acute GI bleeding is a common presentation in medical practice and can present as a life-threatening abdominal emergency. Bleeding from the small intestinal is only found in 5–10% of patients presenting with a GI bleed [4]. The main aetiologies of small bowel intestinal bleeding include:

- Meckel’s diverticulum and inflammatory bowel disease are common in patients <40 years old, whereas angioectasia and ulcers secondary to anti-inflammatory medications are more common in patients >40 years old [4]. There are only a few case reports of a jejunal GIST being the cause of small intestinal bleeding.

- Upper and lower GI endoscopy remained the first line investigation of GI bleeding. Small intestinal bleeding is a diagnostic challenge as this region is inaccessible by conventional endoscopy. The imaging modalities required after negative upper and lower GI endoscopy include capsule endoscopy, CT angiography, conventional CT scan with IV +/-oral contrast, double balloon enteroscopy and magnetic resonance enterography [4]. CT scan features of small intestinal GISTs include a well-circumscribed extraluminal mass with homogeneous enhancement in small tumours and heterogeneous enhancement due to a necrotic centre in large tumours. Lymph node enlargement is not a feature of GIST. The liver and peritoneum are the specific sites for metastases if present [5].

In our case the intraoperative findings were compatible with the CT scan description.

As our patient became unstable, interventional angiography, even if the facilities had been available in our Institute, would not have been appropriate and so we proceeded to an emergency laparotomy.

To achieve curative treatment of a GIST, complete tumour excision with negative margins is required. Lymph node dissection is not required [2, 6]. In spite of complete excision with clear margins, GISTs tend to recur in ~50% of cases [6]. According to the Armed Forces Institutes of Pathology criteria and modified NIH criteria the tumour in our patient was classified as low risk for recurrence with no need for adjuvant imatinib therapy [6]. However recent research demonstrates that GI bleeding is due to tumour perforation through the mucosa and therefore should be treated similarly to cases where there has been tumour rupture, which changes the risk to high. These studies suggest that GI bleeding could be an independent risk factor for recurrence and therefore these patients require adjuvant treatment with imatinib [2, 7, 8].

Most GISTs (70–80%) have KIT mutations and less commonly have mutations in platelet-derived growth factor receptor alpha (PDGFRα) (10%) and wild-type (10–15%) [6]. GISTs with c-KIT D816V and PDGFRα D842V mutations are highly resistant to imatinib therapy [6, 9, 10]. These were negative in our patient and thus adjuvant imatinib therapy was initiated.

**CONCLUSION**

Small intestinal GISTs should be considered when managing patients with obscure GI bleeding. Contrast CT scan seems to be an effective tool to diagnose small intestinal bleeding GISTs that are inaccessible by conventional endoscopy.

**ACKNOWLEDGMENT**

We would like to thank Mr. Michael Ibrahim for editing English language of the manuscript.
CONFLICT OF INTEREST STATEMENT
None declared.

FUNDING
None.

REFERENCES
1. Brogna B, Imbriani GC, Forte NR, Schettino M, Morelli R, Venditti M, et al. Multifocal gastrointestinal stromal tumor: a case report with CT, surgical, and histopathologic correlation. Radiol Case Rep 2019;14:962–6.
2. Mahmoud S, Salman H, Salami M. A rare case report of locally recurrent hemorrhagic duodenal gastrointestinal stromal tumor: therapeutic challenges and review of prognostic indicators for recurrence. J Surg Case Rep 2020;1:1–4.
3. Liyanage ASD, Thalgaspitiya SPB, Kalaiselvan R, Rajaganeshan R. A rare case of life-threatening bleeding caused by a Jejunal GIST. Surg Case Rep 2019. doi: 10.31487/j.SCR.2019.06.04.
4. Dualim DM, Loo GH, Rajan R, Nik Mahmood NRK. Jejunal GIST: hunting down an unusual cause of gastrointestinal bleed using double balloon enteroscopy. A case report. Int J Surg Case Rep 2019;60:303–6.
5. Abdel-Monem S, Enaba MM, Hassan TA, Attya MA. Multislice CT imaging of gastrointestinal stromal tumors (GISTs). Egypt J Radiol Nuclear Med 2011;42:1–7.
6. Balachandran VP, Ronald P. DeMatteo. GIST tumors: who should get imatinib and for how long? Adv Surg 2014;48:165–83.
7. Liu Q, Kong F, Zhou J, Dong M, Dong Q. Management of hemorrhage in gastrointestinal stromal tumors: a review. Cancer Manag Res 2018;10:735–43.
8. Liu Q, Li Y, Dong M, Kong F, Dong Q. Gastrointestinal bleeding is an independent risk factor for poor prognosis in GIST patients. Biomed Res Int 2017 7152406. doi: 10.1155/2017/7152406.
9. Heinrich MC, Griffith D, McKinley A, Patterson J, Presnell A, Ramachandran A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with Imatinib-resistant gastrointestinal stromal Tumors. Clin Cancer Res 2012;18:4375–84.
10. Nishida T, Blay J-Y, Hirota S, Kitagawa Y, Kang Y-K. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer 2016;19:3–14.